Wednesday, 20 Nov 2019

You are here

Upadacitinib (RINVOQ) FDA Approved for Rheumatoid Arthritis

The US Food and Drug Administration (FDA) on Friday, August 16, approved AbbVie JAK1 inhibitor, Rinvoq (upadacitinib) for adults with  rheumatoid arthritis with moderately to severely active disease either not responding to, or intolerant of, methotrexate (MTX). 

The approved once daily dose is 15 mg qd. The drug may be used with MTX or other DMARDs but should not be combined with other JAK inhibitors or biologic agents.

There is a Boxed Warning for serious infection, malignancy and thrombosis risks:

  • Serious infections including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections
  • Hold RINVOQ if a serious infection develops and until the infection is controlled
  • Test for latent tuberculosis prior to starting RINVOQ; if positive, start TB treatment prior to starting RINVOQ
  • Monitor all patients for active tuberculosis during treatment
  • Lymphoma and other malignancies have been observed in patients treated with RINVOQ
  • Thrombosis, including deep vein thrombosis, pulmonary embolism, and arterial thrombosis, have occurred in patients treated with RINVOQ

Other precautions and warnings include:

  • Avoid initiation or interrupt RINVOQ if: A) absolute lymphocyte count is less than 500 cells/mm3; B) absolute neutrophil count is less than 1000 cells/mm3 or C) hemoglobin level is less than 8 g/dL
  • Consider the risks and benefits prior to treating patients who may be at increased risk of thrombosis. Promptly evaluate patients with symptoms of thrombosis and treat appropriately
  • Use with caution in patients who may be at increased risk for gastrointestinal perforations
  • RINVOQ may cause fetal harm based on animal studies. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception

The full package insert information can be found here https://buff.ly/307rKXv

AbbVie has announced that Rinvoq will be available at a list price $59,000 a year (or $5,174 a month). d on the duration of the treatment and individual healthcare plans. As expected, there will be a co-pay card to reduce out-of-pocket costs to $5 per month for eligible, commercially-insured patients, and a patient support program as well. By comparison, wholesale cost for Humira is $62,088. For Xeljanz is $53,772. Olumiant (relatively cheaper) is $25,642.  

This is the third JAK inhibitor to be FDA approved for use in RA.

Rinvoq (upadacitinib) is also being studied for use in other conditions such as psoriatic arthritis, Crohn’s disease and ulcerative colitis.

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

ACR 2019 – Best of the Plenary Sessions

The ACR Plenary Sessions featured some of the best research presented on Sunday, Monday, and Tuesday in Atlanta. Here are my seven notable highlights from the Plenaries.

New EMA Warnings for Tofacitinib in Patients at Risk for Clots

The European Medicines Agency safety committee (PRAC) has concluded that Xeljanz (tofacitinib - TOFA) could increase the risk of blood clots in the lungs and in deep veins in patients who are already at high risk for venous thromboembolic events. The PRAC is recommending that TOFA should be used with caution in patients at high risk of blood clots (VTE), regardless of dose used.

FDA Approves Ustekinumab for Ulcerative Colitis

Ustekinumab (Stelara) is now FDA-approved to treat moderately to severely active ulcerative colitis, said drugmaker Janssen on Monday, in addition to its indications for psoriasis, psoriatic arthritis, and Crohn's disease.

Interleukin Targeted Biologics Increase Risks of Infection

A systematic review of the literature shows that, compared to placebo, the use of non-TNF, interleukin inhibitor biologics may be associated with significantly higher rates of serious infections, opportunistic infections, and cancer.

Biologics Lead the Way in Drug Price Increases

Reuters has reported the results of a recent Institute for Clinical and Economic Review (ICER) analysis showing that biologics, especially Humira and Rituxan, are leading the way in the cost of drugs in the USA. All told, Humira and Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. drug spending. ICER said their analysis points to price hikes that were more than twice the rate of medical inflation and were not warranted by any new clinical evidence.